Expert opinion on investigational drugsHumansMaleReceptorsAndrogenSignal Transduction
Androgen receptor pathway signaling inhibitors in development for prostate cancer therapy.
Sara Bleve, Pier Vitale Nuzzo, Abdul Baseet Arham, Aaron Holmes, Scott T Tagawa
Published: 202510.1080/13543784.2025.2573647
Abstract
INTRODUCTION: Prostate cancer (PC), including castration-resistant disease (CRPC), remains largely driven by dysregulated androgen receptor (AR) signaling. While androgen deprivation therapy (ADT) combined with next-generation AR inhibitors improves…
Preview only. Read the full abstract at the source